March 31st 2023
The 10-year cumulative local recurrence rate in patients with early breast cancer receiving accelerated partial breast irradiation with multi-catheter brachytherapy does not significantly differ from those receiving whole-breast irradiation following breast-conserving surgery.
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
View More
41st Annual Miami Breast Cancer Conference®
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
22nd Annual International Congress on the Future of Breast Cancer® West
07/28/2023 - 07/29/2023
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Community Practice Connections™: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates From San Antonio
View More
22nd Annual International Congress on the Future of Breast Cancer® East
07/14/2023-07/15/2023
View More
22nd Annual International Congress on the Future of Breast Cancer® East
07/14/2023-07/15/2023
View More
Oncology Consultations®: Clinical Impact of HER2-Low Expressing Breast Cancer and Novel Targeted Therapies to Address Unmet Needs in Care
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
Advances In™: Meeting Unmet Clinical Needs in TNBC and HR+ Breast Cancer with TROP2-Targeted Regimens
View More
Medical Crossfire®: Clinical Decision-Making Under New Paradigms for HR+/HER2- Breast Cancer
View More
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
View More
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
View More
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
View More
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
View More
Expanding Options Beyond Conventional Therapy in HR+ Breast Cancer to Overcome Unmet Needs
View More
Cases and Conversations™: Nursing Considerations for the Management of ER+ Breast Cancer
View More
Community Practice Connections™: Incorporating Novel HER2-Targeted Therapies Into Treatment Algorithms Across Metastatic Breast Cancer
View More
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
View More
Patient, Provider, and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of TNBC
View More
Medical Crossfire®: Evaluating the Potential Role of Next-Generation Selective Estrogen Receptor Degraders in the ER+/HER2- Breast Cancer Treatment Paradigm
View More
Tumor Board: How The Experts Approach Personalized Care Plans in ER-Positive Breast Cancer
View More
Community Practice Connections™: Individualizing Therapy for High-Risk Early-Stage Hormone Receptor-Positive Breast Cancer
View More
39th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™
View More
39th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™
View More
Community Practice Connections™: Testing and Utilization of Ki-67 and Other Prognostic Markers for Clinical Decision-Making in HR-Positive, HER2-Negative Breast Cancer
View More
FDA Expands Abemaciclib Approval to Include HR+ HER2– Node+ High-Risk Breast Cancer
March 3rd 2023Patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer at a high risk of relapse who are eligible for treatment with abemaciclib can be identified via nodal status as well as tumor size and grade.
FDA Approves Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast Cancer
February 3rd 2023Patients with pre-treated, unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.
HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care
Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.
Managing HER2+ Breast Cancer With Leptomeningeal Metastases
Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.
Agents in Development for HER2+ Breast Cancer
Experts share brief insights on novel agents in development for HER2+ breast cancer and consider how they may impact the treatment landscape.
Optimizing Care of Patients on T-DXd for HER2+ mBC With CNS Disease
Centering discussion on trastuzumab deruxtecan use in HER2+ metastatic breast cancer, experts elucidate adverse event management and concurrent radiation therapy.
Veliparib/Cisplatin May Improve Survival Vs Placebo in BRCA-Like Metastatic TNBC
January 19th 2023Cisplatin plus veliparib appears to improve progression-free survival among patients with BRCA-like metastatic triple-negative breast cancer, but not in those with non–BRCA-like metastatic breast cancer.
FDA Gives Investigational Drug Fast Track Designation for Advanced Breast Cancer Subtype
January 13th 2023The investigational drug CFI-402257 alone and in combination with fulvestrant received fast track designation from the FDA for patients with estrogen receptor–positive, HER2-negative advanced breast cancer.
HER2+ Metastatic Breast Cancer: Guidance on MRI Use After CNS Radiation
A brief review on how best to use MRI following CNS-directed radiation therapy in patients with HER2+ metastatic breast cancer.
Patient Case 3: HER2+ Metastatic Breast Cancer With CNS Disease
Following review of the final patient scenario, panelists consider later-line treatment options in the setting of multiply relapsed HER2+ metastatic breast cancer.